ClinicalTrials.gg
CompletedNCT01897532Updated Apr 4, 2019Results posted

Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus (CARMELINA)

A Phase 4 interventional study of Placebo and Linagliptin in Diabetes Mellitus, Type 2, sponsored by Boehringer Ingelheim. Completed at 649 sites in 27 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-04-04.

Sponsored by Boehringer Ingelheim · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
6,991
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 67 studies testing linagliptin in Diabetes Mellitus, Type 2 — 1 open to participants now, 1 under way, none of them phase 3. Linagliptin · Diabetes Mellitus, Type 2.

Enrollment
Largest of 67
6,991 · median 175
Started
2013
with 6 others
Phase 4
22 of 67
1 open now
Registered
35th of 67
by date
Lead sponsor
36 of 67
Boehringer Ingelheim

Among the 67 studies testing linagliptin in Diabetes Mellitus, Type 2, this one has the largest enrollment, is one of 7 that started in 2013, is one of 22 in phase 4, and was the 35th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

1 of the 67 studies testing linagliptin in Diabetes Mellitus, Type 2 is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About linagliptin

Linagliptin: first FDA approval 2011 (TRADJENTA), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 67 studies testing linagliptin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The aim of the study is to investigate the longterm impact on cardiovascular morbidity, mortality and renal function of treatment with linagliptin in a selected population of patients with Type 2 diabetes mellitus (T2DM) and to compare outcomes against placebo, on a background of standard of care.

03

Conditions studied

  • Diabetes Mellitus, Type 2
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Documented diagnosis of T2DM before visit 1(screening).
  2. Male or female patients who are drug-naïve or pre-treated with any antidiabetic background medication, excluding treatment with Glucagon-like Peptide 1 (GLP-1) receptor agonists, Dipeptidyl-peptidase 4 (DPP-4) inhibitors or Sodium Glucose Linked Transporter 2 (SGLT-2) inhibitors if => consecutive 7 days.
  3. Stable antidiabetic background medication (unchanged daily dose) for at least 8 weeks prior to randomization. If insulin is part of the background therapy, the average daily insulin dose should not have changed by more than 10% within the 8 weeks prior to randomization compared with the daily insulin dose at randomization.
  4. of => 6.5% and \<= 10.0% at Visit 1 (screening)
  5. Age => 18 years at Visit 1(screening). For Japan only: Age => 20 years at Visit 1
  6. (BMI) \<= 45 kg/m2 at Visit 1 (screening)
  7. Signed and dated written by date of Visit 1(screening) in accordance with Good Clinical Practice (GCP) and local legislation prior to any study related procedure
  8. High risk of cardiovascular (CV) events defined by: 1) albuminuria (micro or macro) and previous macrovascular disease and/or 2) impaired renal function with predefined Urine Albumin Creatinine Ratio (UACR)

Exclusion criteria

Exclusion criteria:

  1. Type 1 diabetes mellitus.
  2. Treatment (=> 7 consecutive days) with GLP-1 receptor agonists, other DPP-4 inhibitors or SGLT-2 inhibitors prior to . Note: This also includes clinical trials where these antidiabetic drugs have been provided to the patient.
  3. Active liver disease or impaired hepatic function, defined by serum levels of either (ALT) (SGPT), Aspartate transaminase (AST) (SGOT), or alkaline phosphatase (AP) => 3 x (ULN) as determined at Visit 1.
  4. Estimated (eGFR) \<15 ml/min/1.73 m2 (severe renal impairment or End Stage Renal Disease (ESRD), Modification of Diet in Renal Disease (MDRD) formula), as determined during screening at Visit 1 and/or the need for maintenance dialysis.
  5. Any previous (or planned within next 12 months) bariatric surgery (open or laparoscopic) or intervention (gastric sleeve).
  6. Pre-planned coronary artery re-vascularisation (PCI, CABG) or any previous PCI and/or CABG \<= 2 months prior informed consent.
  7. Known or allergy to the products or its .
  8. Any previous or current alcohol or drug abuse that would interfere with trial participation in the opinion of the investigator.
  9. Participation in another trial with an investigational drug ongoing or within 2 months prior to visit 1 (screening).
  10. Pre-menopausal women (last menstruation = 1 year prior to informed consent) who are nursing or pregnant, are of and are not practicing an acceptable method of (acceptable methods of birth control include tubal ligation, transdermal patch, intra uterine devices/systems (IUDs/IUSs), oral, implantable or injectable contraceptives, sexual abstinence (if allowed by local authorities), double barrier method and vasectomised partner) or do not plan to continue using acceptable method of birth control throughout the study and do not agree to submit to periodic pregnancy testing during participation in the trial.
  11. Patients considered unreliable by the investigator concerning the requirements for follow up during the study and/or compliance with study drug administration, have a less than 5 years for non-CV causes, or have cancer other than non-melanoma skin cancer within last 3 years, or has any other condition than mentioned which in the opinion of the investigator, would not allow safe participation in the study.
  12. Acute coronary syndrome (ACS), diagnosed \<= 2 months prior to visit 1 (screening).
  13. Stroke or (TIA) \<= 3 months prior to visit 1 (screening).
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
6,991 participants (actual)

Study arms

  • Experimental
    Linagliptin

    Drug: Linagliptin

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Time to the First Occurrence of Any of the Following Adjudication-confirmed Components of the Primary Composite Endpoint 3-point Major Adverse Cardiovascular (CV) Events (3-point MACE): CV Death, Non-fatal Myocardial Infarction (MI) or Non-fatal Stroke.

    Time to event analysis of patients with first occurrence of any of the following adjudication-confirmed components of the primary composite endpoint (3-point MACE): CV death, non-fatal MI or non-fatal stroke. The percentage of observed patients with first occurrence of any of the following adjudication-confirmed components of the primary composite endpoint (3-point MACE) was reported.

    Time frame: From randomization to individual end of observation; up to 4.3 years

Secondary outcomes

  1. Time to the First Occurrence of Any of the Following Adjudication-confirmed Components: Renal Death, Sustained End Stage Renal Disease (ESRD), or Sustained Decrease of 40% or More in Estimated Glomerular Filtration Rate (eGFR).

    Time to the first occurrence of any of the following adjudication-confirmed components: renal death, sustained ESRD, or sustained decrease of 40% or more in eGFR. The percentage of observed patients with first occurrence of any of the following adjudication-confirmed components: renal death, sustained ESRD, or sustained decrease of 40% or more in eGFR was reported.

    Time frame: From randomization to individual end of observation; up to 4.3 years

07

Results

Posted Jan 25, 2019

Participant flow

Prior to initiation of any trial-related procedure, all patients were informed about the trial verbally and in writing by the investigator. The patients signed and dated the informed consent before any study related procedures.

Discontinuation From Treatment
Participant flow — Discontinuation From Treatment
MilestonePlaceboLinagliptin
Started34923499
Treated34853494
Completed25302660
Not completed962839
Withdrew: Not treated75
Withdrew: Other reason than specified196176
Withdrew: Withdrawal by subject333281
Withdrew: Non compliance2415
Withdrew: Adverse event/ cv outcome event402362
Discontinuation From Trial
Participant flow — Discontinuation From Trial
MilestonePlaceboLinagliptin
Started34923499
Treated34853494
Completed34303458
Not completed6241
Withdrew: Not treated75
Withdrew: Patient lost to follow-up for mace5536

Outcome measures

PrimaryTime to the First Occurrence of Any of the Following Adjudication-confirmed Components of the Primary Composite Endpoint 3-point Major Adverse Cardiovascular (CV) Events (3-point MACE): CV Death, Non-fatal Myocardial Infarction (MI) or Non-fatal Stroke.

Time to event analysis of patients with first occurrence of any of the following adjudication-confirmed components of the primary composite endpoint (3-point MACE): CV death, non-fatal MI or non-fatal stroke. The percentage of observed patients with first occurrence of any of the following adjudication-confirmed components of the primary composite endpoint (3-point MACE) was reported.

Time frame:
From randomization to individual end of observation; up to 4.3 years
Reported as:
Number · percentage of participants
Time to the First Occurrence of Any of the Following Adjudication-confirmed Components of the Primary Composite Endpoint 3-point Major Adverse Cardiovascular (CV) Events (3-point MACE): CV Death, Non-fatal Myocardial Infarction (MI) or Non-fatal Stroke.
percentage of participantsPlaceboLinagliptin
Time to the First Occurrence of Any of the Following Adjudication-confirmed Components of the Primary Composite Endpoint 3-point Major Adverse Cardiovascular (CV) Events (3-point MACE): CV Death, Non-fatal Myocardial Infarction (MI) or Non-fatal Stroke.12.112.4
Statistical analysis
  • Placebo vs Linagliptin · Regression, Cox · p = 0.0002 (p-value for Hazard ratio (HR) ≥1.3 (1-sided)) · Hazard ratio (hr): 1.02 · 95% CI 0.89 to 1.17Based on a Cox regression model with terms for treatment group and region.
  • Placebo vs Linagliptin · Regression, Cox · p = 0.6301 (p-value for HR ≥1.0 (1-sided).) · Hazard ratio (hr): 1.02 · 95% CI 0.89 to 1.17Based on a Cox regression model with terms for treatment group and region.
SecondaryTime to the First Occurrence of Any of the Following Adjudication-confirmed Components: Renal Death, Sustained End Stage Renal Disease (ESRD), or Sustained Decrease of 40% or More in Estimated Glomerular Filtration Rate (eGFR).

Time to the first occurrence of any of the following adjudication-confirmed components: renal death, sustained ESRD, or sustained decrease of 40% or more in eGFR. The percentage of observed patients with first occurrence of any of the following adjudication-confirmed components: renal death, sustained ESRD, or sustained decrease of 40% or more in eGFR was reported.

Time frame:
From randomization to individual end of observation; up to 4.3 years
Reported as:
Number · percentage of participants
Time to the First Occurrence of Any of the Following Adjudication-confirmed Components: Renal Death, Sustained End Stage Renal Disease (ESRD), or Sustained Decrease of 40% or More in Estimated Glomerular Filtration Rate (eGFR).
percentage of participantsPlaceboLinagliptin
Time to the First Occurrence of Any of the Following Adjudication-confirmed Components: Renal Death, Sustained End Stage Renal Disease (ESRD), or Sustained Decrease of 40% or More in Estimated Glomerular Filtration Rate (eGFR).8.89.4
Statistical analysis
  • Placebo vs Linagliptin · Regression, Cox · p = 0.6918 (p-value for HR ≥1.0 (1-sided)) · Hazard ratio (hr): 1.04 · 95% CI 0.89 to 1.22Based on a Cox regression model with terms for treatment group and region.

Adverse events

Collected over Adverse events with an onset after the first dose of trial medication up to a period of 7 days after the last permanent study drug stop; up to 4.3 years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo253/3,485 (7.3%)1,343/3,485 (38.5%)1,422/3,485 (40.8%)
Linagliptin250/3,494 (7.2%)1,293/3,494 (37%)1,434/3,494 (41%)
Most frequent serious events
Showing 10 of 1,005
Most frequent serious events
EventPlaceboLinagliptin
PneumoniaInfections and infestations121/348599/3494
Cardiac failureCardiac disorders104/3485104/3494
Acute kidney injuryRenal and urinary disorders100/348596/3494
Cardiac failure congestiveCardiac disorders98/348577/3494
Acute myocardial infarctionCardiac disorders59/348578/3494
Angina unstableCardiac disorders70/348577/3494
Ischaemic strokeNervous system disorders49/348561/3494
Myocardial infarctionCardiac disorders54/348547/3494
Chronic kidney diseaseRenal and urinary disorders32/348549/3494
End stage renal diseaseRenal and urinary disorders45/348538/3494
Most frequent other events
Most frequent other events
EventPlaceboLinagliptin
HypoglycaemiaMetabolism and nutrition disorders1003/34851022/3494
HyperglycaemiaMetabolism and nutrition disorders240/3485208/3494
HypertensionVascular disorders232/3485216/3494
Glomerular filtration rate decreasedInvestigations200/3485202/3494
Urinary tract infectionInfections and infestations162/3485196/3494

Baseline characteristics

Treated set (TS): All patients treated with at least one dose of trial medication. If no trial medication was taken at site during the visit, but the medication kit was dispensed to the patient and not all trial medication was returned, the patient was included in the TS.

Age, Continuous
Age, Continuous(years)PlaceboLinagliptinTotal
Mean65.6 ± 9.1466.1 ± 9.0565.9 ± 9.10
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboLinagliptinTotal
Female124313462589
Male224221484390
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboLinagliptinTotal
Hispanic or Latino127412272501
Not Hispanic or Latino221122674478
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboLinagliptinTotal
American Indian or Alaska Native156159315
Asian333307640
Native Hawaiian or Other Pacific Islander10717
Black or African American217194411
White276928275596
More than one race000
Unknown or Not Reported000
08

Study locations

649 sites
  • Longwood Research
    Huntsville, Alabama 35801, United States
  • Scottsboro Quick Care Clinic
    Scottsboro, Alabama 35768, United States
  • Office of Dr. Terence T. Hart MD
    Tuscumbia, Alabama 35674, United States
  • Arrowhead Health Centers
    Glendale, Arizona 85306, United States
  • Precision Trials, LLC
    Phoenix, Arizona 85032, United States
  • Harrisburg Family Medical Center
    Harrisburg, Arkansas 72432, United States
  • Cardiology and Medicine Clinic
    Little Rock, Arkansas 72204, United States
  • Little Rock Diagnostic Clinic
    Little Rock, Arkansas 72205, United States
  • Kaiser Permanente - San Diego, Bonita
    Bonita, California 91902, United States
  • John Muir Physician Network Clinical Research Center
    Concord, California 94520, United States
  • Valley Research
    Fresno, California 93720, United States
  • VA Loma Linda Healthcare System
    Loma Linda, California 92357, United States
  • Long Beach Center for Clinical Research
    Long Beach, California 90807, United States
  • Clearview Medical Research, LLC
    Los Angeles, California 90019, United States
  • National Research Institute
    Los Angeles, California 90057, United States
  • Office of Dr. Richard S. Cherlin
    Los Gatos, California 95032, United States
  • Coastal Medical Research Group
    Los Osos, California 93402, United States
  • Novo Research, Incorporated
    Modesto, California 95350, United States
  • Providence Clinical Research
    North Hollywood, California 91606, United States
  • Northridge Clinical Research Inc.
    Northridge, California 91324, United States
  • Carr Cardiology
    Oceanside, California 92056, United States
  • Center for Clinical Trials of Sacramento, Incorporated
    Sacramento, California 95823, United States
  • North America Research Institute
    San Dimas, California 91773, United States
  • Trinitas Research, Incorporated
    San Jose, California 95116, United States
  • Metabolic Institute of America
    Tarzana, California 91356, United States
  • Center for Clinical Trials of San Gabriel
    West Covina, California 91790, United States
  • Western Nephrology & Metabolic
    Arvada, Colorado 80002, United States
  • South Denver Nephrology
    Denver, Colorado 80210, United States
  • Colorado Center for Bone Research, P.C.
    Golden, Colorado 80401, United States
  • Helix Biomedics LLC
    Boynton Beach, Florida 33435, United States
  • Orthopedic Research Institute
    Boynton Beach, Florida 33437, United States
  • Nova Clinical Research, LLC
    Bradenton, Florida 34209, United States
  • PAB Clinical Research
    Brandon, Florida 33511, United States
  • Meridien Research
    Brooksville, Florida 34601, United States
  • Southeast Clinical Research, LLC
    Chiefland, Florida 32626, United States
  • BayCare Medical Group
    Clearwater, Florida 33756, United States
  • Cohen Medical Research Associates, LLC
    Delray Beach, Florida 33446, United States
  • Innovation Medical Research Center, Inc
    Doral, Florida 33166, United States
  • Integrative Research Associates
    Fort Lauderdale, Florida 33312, United States
  • Jellinger and Lerman, MD, PA dba The Center for Diabetes and Endocrine Care
    Fort Lauderdale, Florida 33312, United States
  • Direct Helpers Medical Center, Inc
    Hialeah, Florida 33012, United States
  • Universal Clinical Research
    Hialeah, Florida 33012, United States
  • Homestead Associates in Research
    Homestead, Florida 33032, United States
  • St. Vincent's Cardiology
    Jacksonville, Florida 32216, United States
  • Care Partners Clinical Research LLC
    Jacksonville, Florida 32277, United States
  • Altus Research, Inc.
    Lake Clarke Shores, Florida 33406, United States
  • Meridien Research
    Lakeland, Florida 33805, United States
  • Precision Research Organization
    Miami Lakes, Florida 33016, United States
  • Clinical Research of Miami
    Miami, Florida 33126, United States
  • Prestige Clinical Research Center, Inc.
    Miami, Florida 33133, United States
  • Jesscan Medical Research, Internal Medicine
    Miami, Florida 33134, United States
  • Clintex Research Group, Inc. Research
    Miami, Florida 33135, United States
  • University of Miami
    Miami, Florida 33136, United States
  • Florida Medical Center & Research Inc
    Miami, Florida 33142, United States
  • A+ Research Incorporated
    Miami, Florida 33144, United States
  • Unlimited Medical Research, LLC
    Miami, Florida 33144, United States
  • Regenerate Clinical Trials
    Miami, Florida 33155, United States
  • Sanitas Research
    Miami, Florida 33155, United States
  • Future Care Solution, LLC
    Miami, Florida 33165, United States
  • Research Institute of South Florida Inc
    Miami, Florida 33173, United States
  • Tellus Clinical Research, Incorporated
    Miami, Florida 33173, United States
  • New Horizon Research Center
    Miami, Florida 33175, United States
  • Kendall South Medical Center, Inc
    Miami, Florida 33185, United States
  • Coral Research Clinic Corp
    Miami, Florida 33186, United States
  • School of Clinical Research
    North Miami Beach, Florida 33144, United States
  • Harmony Clinical Research, Incorporated
    North Miami Beach, Florida 33162, United States
  • Magnolia Research Group
    Ocala, Florida 34471, United States
  • Family Medical Center
    Orlando, Florida 32806, United States
  • Peninsula Research, Inc.
    Ormond Beach, Florida 32174, United States
  • Infinity Clinical Research, LLC
    Plantation, Florida 33317, United States
  • Meridien Research
    Saint Petersburg, Florida 33709, United States
  • Professional Health Care of Pinellas, Inc.
    Saint Petersburg, Florida 33713, United States
  • Intercoastal Medical Group, Endocrinology
    Sarasota, Florida 34232, United States
  • Meridien Research
    Tampa, Florida 33634, United States
  • Metabolic Research Institute
    West Palm Beach, Florida 33401, United States
  • Emory University
    Atlanta, Georgia 30303, United States
  • Laureate Clinical Research Group, LLC
    Atlanta, Georgia 30308, United States
  • Bainbridge Medical Associates
    Bainbridge, Georgia 39819, United States
  • Atlanta Heart Specialists, LLC
    Cumming, Georgia 30041, United States
  • McGarity, Jr., William C.
    Decatur, Georgia 30035-4000, United States
  • Atlanta Heart Specialists, LLC
    Tucker, Georgia 30084, United States
  • Belleville Family Medical Associates, Ltd
    Belleville, Illinois 62220, United States
  • Cedar-Crosse Research Center
    Chicago, Illinois 60607, United States
  • Chicago Clinical Research Institute, Inc.
    Chicago, Illinois 60607, United States
  • Associates in Endocrinology, Incorporated
    Elgin, Illinois 60124, United States
  • Kidney Care Center, Nephrology
    Joliet, Illinois 60435, United States
  • American Health Network
    Avon, Indiana 46123, United States
  • American Health Network of Indiana, LLC
    Franklin, Indiana 46131, United States
  • American Health Network of Indiana, LLC
    Greenfield, Indiana 46140, United States
  • American Health Network of Indiana, LLC
    Muncie, Indiana 47304, United States
  • Buynak Clinical Research
    Valparaiso, Indiana 46383, United States
  • Northeast Iowa Medical Education Foundation
    Waterloo, Iowa 50702, United States
  • Iowa Diabetes and Endocrinology Research Center
    West Des Moines, Iowa 50265, United States
  • Cotton-O'Neil Clinical Research Center
    Topeka, Kansas 66606, United States
  • Professional Research Network of Kansas, LLC
    Wichita, Kansas 67203, United States
  • Heartland Research Associates, LLC
    Wichita, Kansas 67205, United States
  • The Research Group of Lexington, LLC
    Lexington, Kentucky 40503, United States
  • Diabetes and Metabolism Associates APMC
    Metairie, Louisiana 70006, United States
  • Tulane University Hospital and Clinic
    New Orleans, Louisiana 70112, United States
  • Maryland Cardiovascular Specialists
    Baltimore, Maryland 21229, United States

Showing the first 100 of 649 sites across 27 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Verhagen C, Janssen J, Minderhoud CA, van den Berg E, Wanner C, Passera A, Johansen OE, Biessels GJ. Chronic kidney disease and cognitive decline in patients with type 2 diabetes at elevated cardiovascular risk. J Diabetes Complications. 2022 Oct;36(10):108303. doi: 10.1016/j.jdiacomp.2022.108303. Epub 2022 Aug 31. PubMed 36116359 ↗
  • Verhagen C, Janssen J, Exalto LG, van den Berg E, Johansen OE, Biessels GJ. Diabetes-specific dementia risk score (DSDRS) predicts cognitive performance in patients with type 2 diabetes at high cardio-renal risk. J Diabetes Complications. 2020 Oct;34(10):107674. doi: 10.1016/j.jdiacomp.2020.107674. Epub 2020 Jul 16. PubMed 32723590 ↗
  • Perkovic V, Toto R, Cooper ME, Mann JFE, Rosenstock J, McGuire DK, Kahn SE, Marx N, Alexander JH, Zinman B, Pfarr E, Schnaidt S, Meinicke T, von Eynatten M, George JT, Johansen OE, Wanner C; CARMELINA investigators. Effects of Linagliptin on Cardiovascular and Kidney Outcomes in People With Normal and Reduced Kidney Function: Secondary Analysis of the CARMELINA Randomized Trial. Diabetes Care. 2020 Aug;43(8):1803-1812. doi: 10.2337/dc20-0279. Epub 2020 May 22. PubMed 32444457 ↗
  • Biessels GJ, Verhagen C, Janssen J, van den Berg E, Zinman B, Rosenstock J, George JT, Passera A, Schnaidt S, Johansen OE; CARMELINA Investigators. Effect of Linagliptin on Cognitive Performance in Patients With Type 2 Diabetes and Cardiorenal Comorbidities: The CARMELINA Randomized Trial. Diabetes Care. 2019 Oct;42(10):1930-1938. doi: 10.2337/dc19-0783. Epub 2019 Aug 9. PubMed 31399442 ↗
  • McGuire DK, Alexander JH, Johansen OE, Perkovic V, Rosenstock J, Cooper ME, Wanner C, Kahn SE, Toto RD, Zinman B, Baanstra D, Pfarr E, Schnaidt S, Meinicke T, George JT, von Eynatten M, Marx N; CARMELINA Investigators. Linagliptin Effects on Heart Failure and Related Outcomes in Individuals With Type 2 Diabetes Mellitus at High Cardiovascular and Renal Risk in CARMELINA. Circulation. 2019 Jan 15;139(3):351-361. doi: 10.1161/CIRCULATIONAHA.118.038352. PubMed 30586723 ↗
  • Rosenstock J, Perkovic V, Johansen OE, Cooper ME, Kahn SE, Marx N, Alexander JH, Pencina M, Toto RD, Wanner C, Zinman B, Woerle HJ, Baanstra D, Pfarr E, Schnaidt S, Meinicke T, George JT, von Eynatten M, McGuire DK; CARMELINA Investigators. Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial. JAMA. 2019 Jan 1;321(1):69-79. doi: 10.1001/jama.2018.18269. PubMed 30418475 ↗
  • Rosenstock J, Perkovic V, Alexander JH, Cooper ME, Marx N, Pencina MJ, Toto RD, Wanner C, Zinman B, Baanstra D, Pfarr E, Mattheus M, Broedl UC, Woerle HJ, George JT, von Eynatten M, McGuire DK; CARMELINA(R) investigators. Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA(R)): a randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and high cardio-renal risk. Cardiovasc Diabetol. 2018 Mar 14;17(1):39. doi: 10.1186/s12933-018-0682-3. PubMed 29540217 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2013 to primary completion in Jan 2018, 54 months.

Results were first posted in Jan 2019, 1 year after primary completion.

Of 132 industry-sponsored phase 4 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 28. This study's 54 months is above that.

Counting every sponsor, half of 452 studies reached it within 24 months; a quarter within 13 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 9, 2013
First posted
Jul 12, 2013
StartActual
Jul 10, 2013
Primary completionActual
Jan 18, 2018
CompletionActual
Jan 18, 2018
Results first posted
Jan 25, 2019
Last update
Apr 4, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 4, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01897532
Responsible party
Sponsor
First posted
Jul 12, 2013
Start date
Jul 10, 2013
Primary completion
Jan 18, 2018
Completion
Jan 18, 2018
Results posted
Jan 25, 2019
Last update
Apr 4, 2019

Study contacts

Boehringer Ingelheim
study chair · Boehringer Ingelheim
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Linagliptin

Start the discussion